Know Cancer

or
forgot password

Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study

Inclusion Criteria


The patients enrolled into the study will include patients who meet the following
criteria:

Cohort 1: IO clinic breast cancer patients

1. Confirmed breast cancer of primary breast cancer with ICD9 code of 174.x, 233.0 or
V10.3

2. Female

3. ≥18 years of age

4. Can provide signed informed consent

5. 1st IO clinic visit ≤3 months prior to enrollment

6. Can read and understand the questionnaires

Cohort 1A: Sub-cohort of IO clinic patients (cases) who meet the following additional
criteria and for whom matched controls have been found from the CSS database.

1. ICD9 code of 174.x or 233.0

2. Diagnosis ≤2 years prior to 1st IO clinic visit

3. Minimum of two IO clinic visits within 7 months of enrollment

4. Provided Baseline Questionnaire

Cohort 2: Matched controls from CSS database for Cohort 1A patients

1. Confirmed breast cancer

2. Female

3. ≥ 18 years of age

4. Matches a patient in the 1A cohort for age at diagnosis (within 2 years), stage at
diagnosis, and time since diagnosis (within 6 months)

5. Can provide informed consent

6. Can read and understand the questionnaires

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Aim 1: Describe treatments received by breast cancer patients receiving physician level practitioner IO care and the cost of IO care.

Outcome Description:

Will also describe how long after diagnosis women with breast cancer seek IO care and differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care. This patient cohort will consist of all female patients with breast cancer seeking IO clinic care. Our analyses will describe how long after diagnosis women with breast cancer seek IO care and describe differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care.

Outcome Time Frame:

Baseline, 6, 12, 24, 36, 48, and 60 months post study enrollment.

Safety Issue:

No

Principal Investigator

Leanna J. Standish, ND, PhD, FABNO

Investigator Role:

Principal Investigator

Investigator Affiliation:

Bastyr University

Authority:

United States: Institutional Review Board

Study ID:

09E-1237-01

NCT ID:

NCT01366248

Start Date:

August 2010

Completion Date:

April 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Red Cedar Wellness CenterBellevue, Washington  98004
Bastyr Integrative Oncology Research CenterKenmore, Washington  98028
Seattle Integrative Oncology at Providence Integrative Cancer CareLacey, Washington  98503
Seattle Cancer Treatment & Wellness CenterRenton, Washington  98057
Seattle Integrative Oncology at Institute of Complementary MedicineSeattle, Washington  98122